内听动脉闭塞综合征的临床与发病机理

目的：探讨内听动脉闭塞综合征的临床与发病机理。方法：分析24例患者年龄、性别及所伴发疾病如高血压病、糖尿病、冠心痛及椎-基底动脉供血不足等。结果：50岁以上，有高血压病、冠心病、糖尿病、椎-基底动脉供血不足者内听动脉闭塞发病明显增加。结论：高血压病、冠心病、糖尿病、椎基底动脉供血不足是内听动脉闭塞综合征的主要危险因素。     

凋亡抑制基因Survivin与膀胱癌

Survivin属于凋亡抑制蛋白家族之一，在人类肿瘤中都有不同程度的表达，其中以膀胱移行细胞癌为著，有抑制细胞凋亡和参与细胞周期的调节作用，对膀胱肿瘤的发生发展起重要作用。他们的高表达也许能为临床诊断和将来靶向治疗提供潜在价值，本文就其生物学特点及在膀胱癌中的研究现状作一概述。     

胃食管反流病与功能磁共振技术

随着对胃食管反流病研究的深入,大脑和食管感觉及胃排空的相互作用越来越受到重视,功能磁共振成像技术,有助于进一步了解胃食管反流病的发病机制。     

重症心源性肺水肿伴休克患者的机械通气治疗

目的研究重症心源性肺水肿伴休克患者机械通气(MV)治疗时通气压力的选择对预后的影响。方法将符合标准的22例患者分为两组对照组9例,常规给予较低通气压力和加强药物治疗;治疗组13例,适当增加通气压力。观察血压、临床症状和动脉血气的变化。结果调整MV后30分钟时,治疗组收缩压迅速由(95±12)mmHg升至(130±15)mmHg(P<0.001),呼吸频率(RR)由(38±11)次/min降至(27±6)次/min(P<0.005),心率(HR)由(126±15)次/min降至(105±12)次/min(P<0.001);对照组上述指标变化不明显。2小时后治疗组的升压药用量减少(70±15)%,对照组则增加(20±5)%;同时在吸氧浓度不变的情况下,治疗组的PaO2由(81±12)mmHg升至(140±15)mmHg(P<0.001),明显高于对照组PaO2的改善。24~48小时内治疗组11例患者(85%)停用升压药,对照组2例(22%)停用。最终治疗组100%的患者好转出院,对照组为45%(P<0.05)。结论与低压力通气相比,适当增加MV通气压力不仅可迅速改善重症心源性水肺肿伴休克患者的低氧血症,也可迅速升高血压,改善心功能,降低病死率。     

血管生长因子在冠心病治疗性血管新生中的应用

血管生长因子在血管新生过程中起着重要作用.大量的动物研究显示在给予血管生长因子后能够有效地促进缺血心肌的血管新生,改善局部血流灌注,提高心功能.但由于临床Ⅱ期试验未取得预期的阳性结果,给治疗性血管新生的应用带来了新的挑战,众多问题有待进一步优化和解决.     

急性心肌梗死急诊介入治疗的临床评价

目的探讨急诊经皮冠状动脉介入治疗术(PCI)对ST段抬高型急性心肌梗死(STAMI)的治疗价值。方法STAMI46例,在发病12h内行急诊冠状动脉造影及直接冠脉支架置入术(DS)或预扩张后支架置入术(PS),观察术中心律失常发生情况,术后TIMI分级、心电图,出院前左室射血分数(LVEF)和住院期间主要不良心脏事件(MACE)等。结果DS组与PS组各项指标无差异,44例达TIMI3级,成功率达95.7%,ST段回落率67.4%,平均LVEF(49.4±9.46)%,术中心律失常发生率21.7%,无MACE发生。结论对于发病12h的STAMI患者,行急诊PCI,可开通梗塞相关动脉(IRA),改善心肌再灌注和近期预后。     

外科治疗56例心脏非黏液性肿瘤的临床分析

目的探讨心脏非黏液性肿瘤临床特点,总结外科治疗经验。方法对我院1996年10月至2005年3月进行外科治疗的56例心脏非黏液性肿瘤的临床资料进行回顾性分析,总结其临床表现、发生部位、肿瘤性质和外科治疗特点等。结果心脏非粘液性肿瘤占本院同期手术患者的0.14%,良性肿瘤28例,恶性肿瘤28例,其中继发性心脏肿瘤8例。良性肿瘤最常见的是生长在心室,共18例;恶性肿瘤最常见的生长部位是心房,共15例。外科治疗行急诊手术者12例。心包开窗引流术2例,探查术1例,术中肿瘤全部切除者26例,部分切除27例,术后住院期间死亡1例。结论心脏非黏液性肿瘤临床表现各异、病理类型多样、病变广泛,手术原则为尽可能切除肿瘤和保持心脏结构的完整性和功能。     

Additional bedtime H2‐receptor antagonist for the control of nocturnal gastric acid breakthrough: A Cochrane systematic review

OBJECTIVES: To assess the effectiveness and safety of additional bedtime H₂‐receptor antagonists (H₂RAs) in suppressing nocturnal gastric acid breakthrough (NAB) via a systematic review. METHODS: Eligible trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 2, 2004), MEDLINE (January 1966–June 2004), EMBASE (January 1980–June 2004) and CINAHL (January 1982–June 2004). Additional hand‐searching was conducted on the proceedings of correlated conferences, eight important Chinese journals and references of all included trials. All randomized controlled trials evaluating H₂RAs for the control of NAB were eligible for inclusion. The systematic review was conducted using methods recommended by The Cochrane Collaboration. RESULTS: Only two randomized crossover studies, comprising 32 participants, met the inclusion criteria. Because the design, dosage and duration of the treatments were different between the studies, it was not possible to conduct meta‐analysis. There were no consistent conclusions found between the two included studies in evaluating H₂RAs for the control of NAB. CONCLUSIONS: No implications for practice at this stage can be concluded. Appropriately designed large‐scale randomized controlled trials with long‐term follow up are needed to determine the effects of additional bedtime H₂RAs in suppressing NAB.     

Translocation between chromosome 5q35 and chromosome 11q13 – an unusual cytogenetic finding in a primary refractory acute myeloid leukemia

Cytogenetic abnormalities are observed in approximately two‐thirds of patients with acute myeloid leukemia (AML). Chromosome rearrangements are associated with specific subtypes of AML and associated prognosis. We report a patient with AML, M2, who was primarily refractory to standard induction chemotherapy with idarubicin and cytarabine. Flow cytometry of a bone marrow aspirate showed aberrant expression of B‐cell markers including CD19. Cytogenetic studies disclosed a translocation between 5q35 and 11q13. Fluorescence in situ hybridization analyses demonstrated that neither the NSD1 nor MLL genes were involved in this case. Further study is required to define conclusively the genes involved and their contribution to pathogenesis in this case.     

超顺磁性氧化铁标记大鼠骨髓基质细胞经门静脉移植MRI活体示踪的研究

目的观察1．5T场强MRI联合动物专用线圈是否可以活体示踪经门静脉移植的纳米级超顺磁性氧化铁颗粒标记的骨髓基质细胞（bone marrow stromal cells BMSCs），为介人性门静脉骨髓基质细胞移植治疗终末期肝脏疾病的研究提供进一步的依据。方法供体大鼠5只，梯度密度离心分离BMSCs，纳米级超顺磁性氧化铁颗粒和脂质体转染BMSCs，体外经普鲁士蓝染色和HE染色确定细胞标记率。受体大鼠15只，分为5组，分别为对照组和纳米级超顺磁性氧化铁颗粒标记的骨髓基质细胞经门静脉移植人正常大鼠肝脏后2h、3d、7d及2周组。1．5T场强MRI联合动物专用线圈行T1W、T2W和T2＊序列扫描，观察肝脏信号改变情况，与对照组比较，并且与组织切片对照。结果纳米级超顺磁性氧化铁颗粒和脂质体转染BMSCs，细胞标记率〉95％。经门静脉移植人正常大鼠肝脏后，T2＊序列扫描显示经标记的BMSCs在肝内显示弥漫性的结节性低信号影，移植后2h到2周均可见到细胞在受体肝脏内存在，组织学切片显示信号缺失部位与铁颗粒标记细胞相一致。结论纳米级超顺磁性铁氧体颗粒标记的大鼠BMSCs经门静脉移植后可以通过1、5T场强行MRI活体示踪，为临床干细胞移植的应用提供可行的示踪方法。